Iradimed Co (IRMD)vsEli Lilly and Company (LLY)
IRMD
Iradimed Co
$83.44
-0.32%
HEALTHCARE · Cap: $1.07B
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 77666% more annual revenue ($65.18B vs $83.81M). LLY leads profitability with a 31.7% profit margin vs 26.8%. LLY appears more attractively valued with a PEG of 1.29. LLY earns a higher WallStSmart Score of 78/100 (B+).
IRMD
Buy60
out of 100
Grade: C
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-81.7%
Fair Value
$56.73
Current Price
$83.44
$26.71 premium
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.3%
Every $100 of equity generates 25 in profit
Keeps 27 of every $100 in revenue as profit
17.0% revenue growth
Earnings expanding 24.8% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Trading at 11.3x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Return on Equity, Profit Margin. Profitability is solid with margins at 26.8% and operating margin at 31.3%. Revenue growth of 17.0% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Market Cap, PEG Ratio. A P/E of 47.8x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
IRMD carries more volatility with a beta of 1.12 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 60/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?